Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Notifies Prefectures of Rules on Online OTC Drug Sales
March 12, 2014
- Settlements Allowing Retroactive Modifications of Transaction Price Not Regarded as Settlements under New Price Cut Rule
March 12, 2014
- HPB’s Economic Affairs Division to Set Up Study Group to Monitor Progress of Roadmap to Promote Generic Drug Use
March 12, 2014
- Revisions of Prefectural Disaster Plans for Drug Distribution Almost Complete
March 11, 2014
- PAFSC’s Committee on Blood Programs Approves Standard Prices of Raw Plasma to Rise in FY2014 Due to Hike in Consumption Tax
March 11, 2014
- PMDA Raises Caution on Teratogenicity of Keratosis Treatment Tigason, Urges Use Only in Serious Cases
March 11, 2014
- Kitasato Daiichi Cannot Secure Flu Vaccine Production Capacity for 20 Million People by State Project Deadline
March 10, 2014
- Opposition Lawmaker Throws Doubts on Key Premium Given to Dellegra
March 7, 2014
- MHLW to Issue Notification Asking Doctors to Refrain from Selecting “No Substitution” Checkbox When Writing Prescriptions
March 7, 2014
- Basic Fees Paid to Pharmacies and Hospitals with Low Price Settlement Rates to Be Reduced under the New Rule from January 2015
March 7, 2014
- Pharmacists Will Be Required to Explain Reasons for Not Dispensing Generics in Case of Generic Name Prescriptions from FY2014
March 7, 2014
- MHLW to Set Up Study Group to Discuss Legislation to Regulate Clinical Research “by April at the Latest”
March 6, 2014
- Market Share of Generics Stood at 46.9% Based on New Calculation Method as of September Last Year: MHLW
March 6, 2014
- Januvia/Glactiv to See 10.1% Price Cut Due to Re-Pricing Following Market Expansion
March 6, 2014
- MHLW to Conduct Hearings with Takeda on Blopress Research Data
March 5, 2014
- Pfizer No. 1 Premium Getter in FY2014 Revision, Non-Japanese Makers Sweep Top 10 List
March 5, 2014
- FY2014 NHI Revision Sees Price Cut of 5.64% without Tax Surcharges, 1,118 Long-Listed Products Subject to New Rule
March 5, 2014
- MHLW to Draft Guidelines to Prevent Misuse of Research Funding, Improper Research Activities
March 5, 2014
- Planned Japanese NIH is Research Supporting Agency, Different from Original: Gov't
March 4, 2014
- MHLW Requests University of Tokyo to Investigate SIGN Trial Issues
March 4, 2014
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…